96 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22651 | Metastatic | Christiane Jungels | Multiple | Cantargia AB | CANFOUR | Trial closed | An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors | christiane.jungels@hubruxelles.be | 1/2 | 1 | |
| 29761 | Breast | UCL St Luc | CICLIBIOME | Trial open for recruitment | CICLIBIOME : A study of the association of the microbiome with treatment outcome of CDK4/6 inhibitors in hormone receptor-positive HER2-negative breast cancer | ||||||
| 29238 | Andrea Gombos | Breast | Institut Jules Bordet | DECRESCENDO | Trial closed for recruitment | De-Escalation of adjuvant ChemotheRapy in HER2-positive, EStrogen reCEptor-negative, Node-negative early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER2 blOckade | accueil.oncologie@hubruxelles.be | 2 | 2 | ||
| 22767 | Conservative or non-conservative breast surgery associated with axillary dissection | Breast | Institut Jules Bordet | DESIGN | Trial closed | The DESIGN trial A randomised, Double-blind, placEbo-controlled Study to assess the effectIveness of pectoral nerves block (Pecs) after breast surGery on Piritramide coNsumption | 3 | 3 | |||
| 28586 | Andrea Gombos | Breast | AstraZeneca | Destiny - Breast06 | Trial closed for recruitment | Phase III Study of Trastuzumab Deruxtecan versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive, Breast Cancer Patients whose Disease has Progressed On Endocrine Therapy in the Metastatic Setting | accueil.oncologie@hubruxelles.be | 3 | 3 | ||
| 29046 | Andrea Gombos | Breast | AstraZeneca | DESTINY- Breast12 | Trial open for recruitment | An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2 Positive Breast Cancer (DESTINY- Breast12) | accueil.oncologie@hubruxelles.be | 3/4 | 3 | ||
| 22712 | HER2+. Metastatic/unresecable | Andrea Gombos | Breast | Daiichi Sankyo | DS8201-A-U302 | Trial closed for recruitment | DS8201-A-U302 A Phase 3, multicenter, randomized, open-label, active-controlled study of DS-8201a, an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2-positive, unresectable and/or metastatic breast cancer | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22713 | HER2 low (+ or ++)/ER+ or ER-. Metastatic | Andrea Gombos | Breast | Daiichi Sankyo | DS8201-A-U303 | Trial closed for recruitment | A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of Physician's choice for HER2-low, HR-positive, unresectable and/or metastatic breast cancer subjects (DS8201-A-U303) | accueil.oncologie@hubruxelles.be | 3 | 3 | |
| 22818 | HER2+. Age Superior to 70 years old | Lissandra Dal Lago | Breast | EORTC | ELDERLY | Trial closed | Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression while on PH / PHM: an open-label multicenter randomized phase II selection trial of the EORTC Elderly Task Force and Breast Cancer Group | lissandra.dallago@hubruxelles.be | 2 | 2 | |
| 28626 | Philippe Aftimos | Multiple | Lilly | EMBER | Trial closed for recruitment | A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Therapies for Patients with ER+, HER2-Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers | philippe.aftimos@hubruxelles.be | 1/1b | 1 | ||
| 28736 | Philippe Aftimos | Breast | Lilly | EMBER-2 | Trial closed | EMBER-2 : A phase 1, open-label, preoperative window study evaluating the biological effects of LY3484356 in post-menopausal women with stage I-III estrogen receptor-positive, HER2-negative breast cancer | philippe.aftimos@hubruxelles.be | 1 | 1 | ||
| 29185 | Philippe Aftimos | Breast | Lilly | EMBER-3 / PILOT415 | Trial closed for recruitment | A Randomized, Open-Label, Phase 3 Study of LY3484356 vs Investigator's Choice of Endocrine Therapy, in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy | philippe.aftimos@hubruxelles.be | 3 | 3 | ||
| 29670 | Philippe Aftimos | Breast | Lilly | EMBER-4 - J2J-MC-JZLH | Trial open for recruitment | J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence | philippe.aftimos@hubruxelles.be | 3 | 3 | ||
| 22716 | ESR1-mut or ESR1-WT | Philippe Aftimos | Breast | Radius Health, Inc | EMERALD | Trial closed for recruitment | Elacestrant Monotherapy for the Treatment of ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-Label, Active-Controlled, Multicenter Trial | philippe.aftimos@hubruxelles.be | 3 | 3 |